BRPI0811245A2 - Composto de carbamoilóxi-aril-alcanoil-aril-piperazinas, composições farmacêuticas que compreendem o composto, e método para tratar dor, ansiedade e depressão administrando o composto. - Google Patents

Composto de carbamoilóxi-aril-alcanoil-aril-piperazinas, composições farmacêuticas que compreendem o composto, e método para tratar dor, ansiedade e depressão administrando o composto.

Info

Publication number: BRPI0811245A2
Authority: BR; Brazil
Prior art keywords: compound; aryl; anxiety; depression; treating pain
Prior art date: 2007-05-14

Application number

BRPI0811245-2A2A

Other languages

English (en)

Inventor

Byong Sung Kwak

Hong Sik Moon

Han-Ju Yi

Young Soon Kang

Eun Hee Chae

Sang Mi Chae

Ki Ho Lee

Dae Joong Im

Original Assignee

Sk Holdings Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-14

Filing date

2008-04-30

Publication date

2014-11-04

2008-04-30 Application filed by Sk Holdings Co Ltd filed Critical Sk Holdings Co Ltd

2014-11-04 Publication of BRPI0811245A2 publication Critical patent/BRPI0811245A2/pt

2021-05-25 Publication of BRPI0811245B1 publication Critical patent/BRPI0811245B1/pt

Links

150000001875 compounds Chemical class 0.000 title abstract 5
208000019901 Anxiety disease Diseases 0.000 title abstract 3
230000036506 anxiety Effects 0.000 title abstract 3
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
241000124008 Mammalia Species 0.000 abstract 2
-1 carbamoyloxy Chemical group 0.000 abstract 1
150000004677 hydrates Chemical class 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/66—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0811245-2A 2007-05-14 2008-04-30 Composto derivado de carbamoilóxi-aril-alcanoil-aril-piperazinas e seus usos BRPI0811245B1 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
KR10-2007-0046708		2007-05-14
KR20070046708		2007-05-14
PCT/KR2008/002470 WO2008140198A1 (en)	2007-05-14	2008-04-30	Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound

Publications (2)

Publication Number	Publication Date
BRPI0811245A2 true BRPI0811245A2 (pt)	2014-11-04
BRPI0811245B1 BRPI0811245B1 (pt)	2021-05-25

Family

ID=40002366

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0811245-2A BRPI0811245B1 (pt)	2007-05-14	2008-04-30	Composto derivado de carbamoilóxi-aril-alcanoil-aril-piperazinas e seus usos

Country Status (17)

Country	Link
US (3)	US8815852B2 (pt)
EP (2)	EP2155736B1 (pt)
JP (2)	JP5605569B2 (pt)
KR (2)	KR101451799B1 (pt)
CN (2)	CN101679400B (pt)
AT (1)	ATE538104T1 (pt)
AU (1)	AU2008251259B2 (pt)
BR (1)	BRPI0811245B1 (pt)
CA (2)	CA2686926C (pt)
DK (1)	DK2155736T3 (pt)
ES (2)	ES2402173T3 (pt)
MX (1)	MX2009012331A (pt)
PL (1)	PL2155736T3 (pt)
PT (1)	PT2155736E (pt)
RU (1)	RU2460731C2 (pt)
WO (2)	WO2008140198A1 (pt)
ZA (1)	ZA200907956B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2686926C (en)	2007-05-14	2016-01-05	Sk Holdings Co., Ltd.	Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound
CN102026988B (zh) *	2008-06-05	2013-07-03	爱思开生物制药株式会社	3-取代的丙胺化合物
US8101642B2 (en)	2008-06-05	2012-01-24	Sk Biopharmaceuticals Co., Ltd.	3-substituted propanamine compounds
WO2011005052A2 (en) *	2009-07-10	2011-01-13	Green Gross Corporation	Novel arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same
KR101810975B1 (ko) *	2010-07-08	2017-12-20	에스케이바이오팜 주식회사	카바모일옥시 아릴알칸노일 아릴피페라진계 화합물을 포함하는 약학적 조성물
CA2877526A1 (en)	2012-06-20	2013-12-27	Novartis Ag	Complement pathway modulators and uses thereof
KR20210062029A (ko) *	2018-10-19	2021-05-28	에스케이바이오팜 주식회사	카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3135756A (en)		1964-06-02		Table ii
US3002976A (en)	1959-10-12	1961-10-03	Paul A J Janssen	1-(2-thienyl)-omega-(4-arylpiperazine)alkanols
DE2325633A1 (de)	1973-05-21	1974-12-12	Boehringer Sohn Ingelheim	Piperazinderivate
NL8202636A (nl)	1982-06-29	1984-01-16	Gist Brocades Nv	Piperazinederivaten, werkwijzen ter bereiding daarvan en farmaceutische preparaten die deze verbindingen bevatten.
US4605655A (en)	1984-03-06	1986-08-12	Bristol-Myers Company	Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives
JPS6175A (ja)	1984-03-06	1986-01-06	ブリストル−マイア−ズ　コムパニ−	神経弛緩剤、１‐フルオロフェニルブチル‐４‐（５‐ハロ‐２‐ピリミジニル）ピペラジン誘導体
GB8909209D0 (en)	1989-04-22	1989-06-07	Wyeth John & Brother Ltd	Piperazine derivatives
US5364849A (en)	1989-04-22	1994-11-15	John Wyeth & Brother, Limited	1-[3 or 4-[1-[4-piperazinyl]]-2 arylpropionyl or butryl]-heterocyclic derivatives
IL94151A (en)	1989-04-22	1995-08-31	Wyeth John & Brother Ltd	History of piperazine, their preparation and pharmaceutical preparations containing them
EP0955296A3 (en)	1989-04-22	2000-01-19	American Home Products Corporation	Tertiary alkyl functionalized piperazine derivatives
GB9125900D0 (en) *	1991-12-05	1992-02-05	Wyeth John & Brother Ltd	Piperazine derivatives
AU6120298A (en) *	1997-03-07	1998-09-22	Takeda Chemical Industries Ltd.	2-peperazinone-1-acetic acid derivatives and their use
ES2128266B1 (es)	1997-07-08	2000-01-16	Vita Invest Sa	Compuestos derivados de tiofeno y benzotiofeno y utilizacion y composicion correspondientes.
DE19934433A1 (de) *	1999-07-22	2001-01-25	Merck Patent Gmbh	N-(Indolcarbonyl-)piperazinderivate
US20020183316A1 (en)	2000-10-27	2002-12-05	Kevin Pan	Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
GB0030710D0 (en)	2000-12-15	2001-01-31	Hoffmann La Roche	Piperazine derivatives
GB0203778D0 (en) *	2002-02-18	2002-04-03	Glaxo Group Ltd	Compounds
ITMI20021327A1 (it)	2002-06-14	2003-12-15	Recordati Chem Pharm	Nuove ossialchilpiperazine
US20040072839A1 (en)	2002-06-14	2004-04-15	Amedeo Leonardi	1-Phenylalkylpiperazines
US6770659B2 (en) *	2002-08-26	2004-08-03	Sk Corporation	Benzoyl piperidine compounds
US20070208166A1 (en)	2003-10-24	2007-09-06	Exelixis, Inc.	Tao Kinase Modulators And Method Of Use
WO2005058823A1 (ja) *	2003-12-17	2005-06-30	Takeda Pharmaceutical Company Limited	ウレア誘導体、その製造法及び用途
PE20060426A1 (es) *	2004-06-02	2006-06-28	Schering Corp	DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
US7598279B2 (en)	2005-04-22	2009-10-06	Sk Holdings Co., Ltd.	Neurotherapeutic azole compounds
ATE492539T1 (de)	2006-08-17	2011-01-15	Hoffmann La Roche	Arylpiperazinderivate und anwendungen davon
CA2686926C (en)	2007-05-14	2016-01-05	Sk Holdings Co., Ltd.	Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound
KR101810975B1 (ko) *	2010-07-08	2017-12-20	에스케이바이오팜 주식회사	카바모일옥시 아릴알칸노일 아릴피페라진계 화합물을 포함하는 약학적 조성물

2008
- 2008-04-30 CA CA2686926A patent/CA2686926C/en active Active
- 2008-04-30 US US12/600,283 patent/US8815852B2/en active Active
- 2008-04-30 MX MX2009012331A patent/MX2009012331A/es active IP Right Grant
- 2008-04-30 AU AU2008251259A patent/AU2008251259B2/en not_active Ceased
- 2008-04-30 ES ES08753266T patent/ES2402173T3/es active Active
- 2008-04-30 DK DK08753270.1T patent/DK2155736T3/da active
- 2008-04-30 WO PCT/KR2008/002470 patent/WO2008140198A1/en not_active Ceased
- 2008-04-30 BR BRPI0811245-2A patent/BRPI0811245B1/pt not_active IP Right Cessation
- 2008-04-30 PL PL08753270T patent/PL2155736T3/pl unknown
- 2008-04-30 CA CA2686547A patent/CA2686547C/en active Active
- 2008-04-30 ES ES08753270T patent/ES2379848T3/es active Active
- 2008-04-30 CN CN2008800163548A patent/CN101679400B/zh not_active Expired - Fee Related
- 2008-04-30 EP EP08753270A patent/EP2155736B1/en not_active Not-in-force
- 2008-04-30 KR KR1020080040394A patent/KR101451799B1/ko not_active Expired - Fee Related
- 2008-04-30 RU RU2009146132/04A patent/RU2460731C2/ru active
- 2008-04-30 EP EP08753266A patent/EP2150550B1/en not_active Not-in-force
- 2008-04-30 CN CN2008800158944A patent/CN101679399B/zh not_active Expired - Fee Related
- 2008-04-30 US US12/600,291 patent/US8541409B2/en active Active
- 2008-04-30 KR KR1020080040393A patent/KR101468553B1/ko active Active
- 2008-04-30 AT AT08753270T patent/ATE538104T1/de active
- 2008-04-30 WO PCT/KR2008/002466 patent/WO2008140197A1/en not_active Ceased
- 2008-04-30 JP JP2010508290A patent/JP5605569B2/ja not_active Expired - Fee Related
- 2008-04-30 PT PT08753270T patent/PT2155736E/pt unknown
- 2008-04-30 JP JP2010508291A patent/JP5387917B2/ja not_active Expired - Fee Related
2009
- 2009-11-12 ZA ZA2009/07956A patent/ZA200907956B/en unknown
2013
- 2013-09-16 US US14/028,284 patent/US8901116B2/en active Active

Also Published As

Publication number	Publication date
EP2150550B1 (en)	2013-02-27
EP2155736A1 (en)	2010-02-24
ZA200907956B (en)	2011-01-26
EP2155736A4 (en)	2010-11-10
EP2155736B1 (en)	2011-12-21
US8901116B2 (en)	2014-12-02
KR101451799B1 (ko)	2014-10-16
US8541409B2 (en)	2013-09-24
ES2402173T3 (es)	2013-04-29
US20140088095A1 (en)	2014-03-27
AU2008251259A1 (en)	2008-11-20
US20110195963A1 (en)	2011-08-11
CA2686926A1 (en)	2008-11-20
WO2008140198A1 (en)	2008-11-20
CN101679400A (zh)	2010-03-24
JP2010526871A (ja)	2010-08-05
KR20080100766A (ko)	2008-11-19
ES2379848T3 (es)	2012-05-04
KR101468553B1 (ko)	2014-12-09
KR20080100765A (ko)	2008-11-19
JP2010526870A (ja)	2010-08-05
BRPI0811245B1 (pt)	2021-05-25
DK2155736T3 (da)	2012-03-12
MX2009012331A (es)	2010-02-10
RU2460731C2 (ru)	2012-09-10
US20120095007A2 (en)	2012-04-19
AU2008251259B2 (en)	2013-02-14
JP5387917B2 (ja)	2014-01-15
JP5605569B2 (ja)	2014-10-15
CA2686547C (en)	2015-12-08
WO2008140197A1 (en)	2008-11-20
HK1141019A1 (en)	2010-10-29
ATE538104T1 (de)	2012-01-15
CN101679399B (zh)	2013-11-06
PT2155736E (pt)	2012-03-28
CN101679399A (zh)	2010-03-24
PL2155736T3 (pl)	2012-09-28
RU2009146132A (ru)	2011-06-20
US20100160331A1 (en)	2010-06-24
CN101679400B (zh)	2013-04-17
EP2150550A1 (en)	2010-02-10
CA2686926C (en)	2016-01-05
EP2150550A4 (en)	2010-11-10
US8815852B2 (en)	2014-08-26
CA2686547A1 (en)	2008-11-20

Legal Events

Date	Code	Title	Description
2018-01-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-05-21	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-07-16	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-10-29	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-02-27	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-03-10	B09X	Republication of the decision to grant [chapter 9.1.3 patent gazette]
2021-04-20	B25A	Requested transfer of rights approved	Owner name: SK BIOPHARMACEUTICALS CO., LTD. (KR)
2021-05-25	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/04/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2024-02-20	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 16A ANUIDADE.
2024-06-04	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2772 DE 20-02-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
NO20091620L (no)	2009-07-09	Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser
EA200971026A1 (ru)	2011-02-28	Новые макроциклические ингибиторы репликации вируса гепатита с
EA201001669A1 (ru)	2011-06-30	Замещенные пиримидин-5-карбоксамиды 281
SG10201806714PA (en)	2018-09-27	C7-fluoro substituted tetracycline compounds
ZA200907956B (en)	2011-01-26	Novel carbamoyloxy arylalkanoyl arylpiperazine compound,pharmaceutical compositions comprising the compound and method for treating pain,anxiety and depression by administering the compound
GEP20125566B (en)	2012-07-10	Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
AR060089A1 (es)	2008-05-21	Tratamiento del dolor
EA200601350A1 (ru)	2007-04-27	Азотсодержащие гетероциклические производные и их фармацевтические применения
EA201101671A1 (ru)	2012-07-30	Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
EA200971041A1 (ru)	2010-08-30	Новые пептидные ингибиторы репликации вируса гепатита с
EA200970296A1 (ru)	2009-10-30	Содержащие диариловый эфир соединения мочевины
ATE545634T1 (de)	2012-03-15	Aromatisches säureether-derivat aus ligustrazin, herstellungsverfahren, pharmazeutische zusammensetzung und anwendung
MX2009011601A (es)	2009-11-10	Agentes terapeuticos utiles para tratar el dolor.
BRPI0412999A (pt)	2006-10-03	2-aminotetralina substituìda para tratamento de depressão
EA201070442A1 (ru)	2010-10-29	НОВЫЕ ИНГИБИТОРЫ sEH И ИХ ПРИМЕНЕНИЕ
IN2012DN02502A (pt)	2015-08-28
MY151072A (en)	2014-03-31	Heteroaryl derivative
NZ592543A (en)	2013-02-22	4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
BR112018069712A2 (pt)	2019-02-05	composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
ATE552246T1 (de)	2012-04-15	Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten
BRPI0407968A (pt)	2006-03-07	derivados de oxamida úteis como inibidores de raf-quinase
EA200800783A1 (ru)	2008-08-29	Композиция тразодона для введения один раз в день
AR062941A1 (es)	2008-12-17	Compuestos para el tratamiento de desordenes metabolicos
NO20085028L (no)	2008-12-02	Substituerte karboksamider
BR112012020060B8 (pt)	2021-05-25	uso de n-((1-((4-hidroxitetrahidro-2h-piran-4-il)metil)piperidin-4-il)metil)-3-isopropil-2-oxo-2,3-dihidro-1h-benzo[d]imidazol-1-carboxamida para tratar doença de alzheimer e demência